Oncolytics Reports HPV-Specific Immune Response Findings

Oncolytics said pelareorep increased HPV-16-specific T-cell and tumor-infiltrating lymphocyte clones in an ongoing study of later-line anal cancer patients. The release cited efficacy signals versus approved therapy but gave no absolute response rates.